Optimum dosing of ipilimumab in melanoma: too little, too late?
Mené dans 21 pays sur 727 patients atteints d'un mélanome non résécable ou de stade métastatique, cet essai de phase III compare le bénéfice-risque, en termes d'amélioration de la survie globale et de la survenue d'événements indésirables, de deux doses d'ipilimumab, 10 mg/kg et 3 mg/kg
Great advances have been made in the treatment of metastatic melanoma in the past 10 years. In 2010, ipilimumab, an anti-CTLA-4 checkpoint inhibitor, was the first drug to show an overall survival advantage for the treatment of metastatic melanoma in two phase 3 trials: one comparing ipilimumab alone at 3 mg/kg versus the gp100 peptide vaccine in previously treated patients, and one comparing ipilimumab 10 mg/kg in combination with dacarbazine versus dacarbazine alone in untreated patients.1,2 A pooled analysis of 1800 patients on trials assessing ipilimumab showed an overall survival plateau at 3 years that persisted over the long term.
The Lancet Oncology , commentaire, 2016